VEGFA and glomerulosclerosis: Evidence has demonstrated that in diabetes, VEGFA is initially upregulated in both the glomeruli and the tubular compartment, in which it induces vascular remodeling, inflammatory processes, glomerulosclerosis, and tubulointerstitial fibrosis; its expression then dramatically drops as the disease progresses, leading to endothelial apoptosis and proteinuria [40].